These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25986253)

  • 1. Frequency characteristics and associations with the defibrillation threshold of ventricular fibrillation in patients with implantable cardioverter defibrillators.
    Iijima K; Chinushi M; Saitoh O; Hasegawa K; Sonoda K; Yagihara N; Sato A; Izumi D; Watanabe H; Furushima H; Aizawa Y; Minamino T
    Intern Med; 2015; 54(10):1175-82. PubMed ID: 25986253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inductionless or limited shock testing is possible in most patients with implantable cardioverter- defibrillators/cardiac resynchronization therapy defibrillators: results of the multicenter ASSURE Study (Arrhythmia Single Shock Defibrillation Threshold Testing Versus Upper Limit of Vulnerability: Risk Reduction Evaluation With Implantable Cardioverter-Defibrillator Implantations).
    Day JD; Doshi RN; Belott P; Birgersdotter-Green U; Behboodikhah M; Ott P; Glatter KA; Tobias S; Frumin H; Lee BK; Merillat J; Wiener I; Wang S; Grogin H; Chun S; Patrawalla R; Crandall B; Osborn JS; Weiss JP; Lappe DL; Neuman S
    Circulation; 2007 May; 115(18):2382-9. PubMed ID: 17470697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ventricular fibrillation frequency from implanted cardioverter defibrillator devices.
    Panfilov I; Lever NA; Smaill BH; Larsen PD
    Europace; 2009 Aug; 11(8):1052-6. PubMed ID: 19549677
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defibrillation testing in everyday medical practice during implantable cardioverter defibrillator implantation in France: analysis from the LEADER registry.
    Sadoul N; Defaye P; Mouton E; Bizeau O; Dupuis JM; Blangy H; Delarche N; Blanc JJ; Lazarus A;
    Arch Cardiovasc Dis; 2013 Nov; 106(11):562-9. PubMed ID: 24200925
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of sotalol on ventricular fibrillation and defibrillation in humans.
    Dorian P; Newman D
    Am J Cardiol; 1993 Aug; 72(4):72A-79A. PubMed ID: 8346730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Short-term and long-term outcome of left heart function after cardioverter defibrillator implantation].
    Takeichi K; Kasanuki H; Ohnishi S; Endoh Y; Hosoda S
    J Cardiol; 1996 Nov; 28(5):277-86. PubMed ID: 8953401
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characteristics of ventricular fibrillation in relation to cardiac aetiology and shock success: A waveform analysis study in ICD-patients.
    Bonnes JL; Keuper W; Westra SW; Zegers ES; Oostendorp TF; Brouwer MA; Smeets JL
    Resuscitation; 2015 Jan; 86():95-9. PubMed ID: 25449343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The NO Regular Defibrillation testing In Cardioverter Defibrillator Implantation (NORDIC ICD) trial: concept and design of a randomized, controlled trial of intra-operative defibrillation testing during de novo defibrillator implantation.
    Bänsch D; Bonnemeier H; Brandt J; Bode F; Svendsen JH; Felk A; Hauser T; Wegscheider K;
    Europace; 2015 Jan; 17(1):142-7. PubMed ID: 25107947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Determination of ventricular vulnerable period and ventricular fibrillation threshold by use of T-wave shocks in patients undergoing implantation of cardioverter/defibrillators.
    Hou CJ; Chang-Sing P; Flynn E; Martinez L; Peterson J; Ottoboni LK; Liem LB; Sung RJ
    Circulation; 1995 Nov; 92(9):2558-64. PubMed ID: 7586357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA; Banchs JE; Depalma S; Young SK; Penny-Peterson ED; Samii SM; Wolbrette DL; Naccarelli GV; Gonzalez MD
    J Cardiovasc Electrophysiol; 2012 Mar; 23(3):296-301. PubMed ID: 21955243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safety and efficacy of intraoperative defibrillation threshold measured by defibrillation safety margin in 52 patients with implantable cardioverter defibrillator].
    Zhang Y; Yuan KD; Tang BP; Ma YT; Zhang YY; Wang J; Li JX; Zhang JH; Xu GJ
    Zhonghua Xin Xue Guan Bing Za Zhi; 2010 Nov; 38(11):975-8. PubMed ID: 21215224
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of induction method on defibrillation threshold and ventricular fibrillation cycle length.
    Zima E; Gergely M; Soós P; Gellér LA; Nemes A; Acsády G; Merkely B
    J Cardiovasc Electrophysiol; 2006 Apr; 17(4):377-81. PubMed ID: 16643358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricular pacing threshold and refractoriness after defibrillation shocks in patients with implantable cardioverter-defibrillators.
    Yu JC; Lauer MR; Young C; Liem B; Peterson J; Ottoboni L; Sung RJ
    Am Heart J; 1996 Jun; 131(6):1121-6. PubMed ID: 8644590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Frequency of ventricular fibrillation as a predictor of defibrillation success during cardiac surgery.
    Strohmenger HU; Lindner KH; Lurie KG; Welz A; Georgieff M
    Anesth Analg; 1994 Sep; 79(3):434-8. PubMed ID: 8067545
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unsuccessful internal defibrillation in Brugada syndrome: focus on refractoriness and ventricular fibrillation cycle length.
    Watanabe H; Chinushi M; Sugiura H; Washizuka T; Komura S; Hosaka Y; Furushima H; Watanabe H; Hayashi J; Aizawa Y
    J Cardiovasc Electrophysiol; 2005 Mar; 16(3):262-6. PubMed ID: 15817083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical predictors of the defibrillation threshold with the unipolar implantable defibrillation system.
    Raitt MH; Johnson G; Dolack GL; Poole JE; Kudenchuk PJ; Bardy GH
    J Am Coll Cardiol; 1995 Jun; 25(7):1576-83. PubMed ID: 7759708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Relationship Between Cardiac Vulnerability and Restitution Properties of the Ventricular Activation Recovery Interval.
    Yamashita S; Yoshida A; Fukuzawa K; Nakanishi T; Matsumoto A; Konishi H; Ichibori H; Hyogo K; Imada H; Hirata K
    J Cardiovasc Electrophysiol; 2015 Jul; 26(7):768-73. PubMed ID: 25810143
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of drive cycle length on initiation of ventricular fibrillation during implantable cardioverter defibrillator threshold testing.
    Sanghvi NK; Lelorier P; Gururaj AV; Monahan KM
    Pacing Clin Electrophysiol; 2006 Sep; 29(9):926-9. PubMed ID: 16981914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ventricular fibrillation waveform characteristics of the surface ECG: Impact of the left ventricular diameter and mass.
    Bonnes JL; Thannhauser J; Nas J; Westra SW; Jansen RMG; Meinsma G; de Boer MJ; Smeets JLRM; Keuper W; Brouwer MA
    Resuscitation; 2017 Jun; 115():82-89. PubMed ID: 28363820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.